Pieris Pharmaceuticals (NASDAQ:PIRS) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Monday.
A number of other equities research analysts have also recently commented on the company. ValuEngine raised Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. William Blair began coverage on Pieris Pharmaceuticals in a research note on Wednesday, January 17th. They issued an “outperform” rating for the company. Finally, HC Wainwright raised their price objective on Pieris Pharmaceuticals from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $10.00.
Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded down $0.06 during trading on Monday, reaching $8.01. The company’s stock had a trading volume of 1,096,262 shares, compared to its average volume of 631,272. Pieris Pharmaceuticals has a 12-month low of $1.88 and a 12-month high of $8.58. The firm has a market capitalization of $358.80, a PE ratio of -10.97 and a beta of -78.08.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The firm had revenue of $3.93 million during the quarter, compared to analysts’ expectations of $1.52 million. The company’s revenue for the quarter was up 400.3% compared to the same quarter last year. equities analysts expect that Pieris Pharmaceuticals will post -0.62 earnings per share for the current year.
In related news, major shareholder Orbimed Advisors Llc sold 147,635 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $5.70, for a total transaction of $841,519.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.05% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in PIRS. State Street Corp purchased a new position in shares of Pieris Pharmaceuticals during the second quarter valued at approximately $2,377,000. Northern Trust Corp purchased a new position in shares of Pieris Pharmaceuticals during the second quarter valued at approximately $1,625,000. TIAA CREF Investment Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the second quarter valued at approximately $649,000. Vanguard Group Inc. bought a new stake in Pieris Pharmaceuticals during the second quarter worth $526,000. Finally, Strs Ohio lifted its holdings in Pieris Pharmaceuticals by 1,028.0% during the fourth quarter. Strs Ohio now owns 112,800 shares of the biotechnology company’s stock worth $851,000 after acquiring an additional 102,800 shares during the period. 50.78% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Pieris Pharmaceuticals (PIRS) Lifted to “Strong-Buy” at BidaskClub” was first reported by Stock Observer and is owned by of Stock Observer. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.thestockobserver.com/2018/02/06/pieris-pharmaceuticals-pirs-lifted-to-strong-buy-at-bidaskclub.html.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.